Oğuzhan Orhan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Oğuzhan Orhan has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Başak Akan Konuk
Computation, Information and Technology (CIT), Technical University of Munich , Munich
1 shared publication - Hazar Gözgöz
Faculty of Medicine, Department of Clinical Biochemistry, Dokuz Eylul University , Izmir
1 shared publication - Pınar Akan
Department of Medical Biochemistry, Faculty of Medicine, Dokuz Eylul University, Izmir 35340, Türkiye
1 shared publication
Latest Publications
- Open Access
- 1 December 2025
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 164 (6) , 933-945
A machine learning model for predicting oligoclonal band positivity using routine cerebrospinal fluid and serum biochemical markers
Objective: To develop and validate a machine learning model for predicting oligoclonal band (OCB) positivity using routine cerebrospinal fluid (CSF) and serum biochemical markers to improve the diagnostic accuracy and efficiency of assessing intrathecal immunoglobulin G (IgG) synthesis. Methods: In this retrospective study (n = 1709), an ensemble model was developed using 8 refined CSF and serum parameters. Combining optimized CatBoost, XGBoost, and LightGBM classifiers, the model was trained and evaluated using a 2-phase workflow, including 5-fold cross-validation and validation on independent internal (n = 342) and external (n = 49) cohorts. Results: The developed ensemble model achieved a receiver operating characteristic–area under the curve (ROC-AUC) of 0.902 on the internal test set, significantly outperforming the conventional IgG index (ROC-AUC, 0.795). At its optimal threshold, the model demonstrated an accuracy of 0.830, with a sensitivity of 0.714 and a specificity of 0.916. On the external validation cohort, it achieved 90% accuracy and 96% sensitivity. Conclusions: A novel machine learning ensemble model accurately predicts OCB positivity using routine laboratory data and demonstrates superior performance compared with the IgG index. This approach represents a significant step in applying artificial intelligence in laboratory medicine, with the potential to enhance diagnostic efficiency. Prospective, multicenter validation is essential for broader clinical implementation.
- 1 December 2025
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 164 (6) , 933-945
Open AccessA machine learning model for predicting oligoclonal band positivity using routine cerebrospinal fluid and serum biochemical markers
Objective: To develop and validate a machine learning model for predicting oligoclonal band (OCB) positivity using routine cerebrospinal fluid (CSF) and serum biochemical markers to improve the diagnostic accuracy and efficiency of assessing intrathecal immunoglobulin G (IgG) synthesis. Methods: In this retrospective study (n = 1709), an ensemble model was developed using 8 refined CSF and serum parameters. Combining optimized CatBoost, XGBoost, and LightGBM classifiers, the model was trained and evaluated using a 2-phase workflow, including 5-fold cross-validation and validation on independent internal (n = 342) and external (n = 49) cohorts. Results: The developed ensemble model achieved a receiver operating characteristic–area under the curve (ROC-AUC) of 0.902 on the internal test set, significantly outperforming the conventional IgG index (ROC-AUC, 0.795). At its optimal threshold, the model demonstrated an accuracy of 0.830, with a sensitivity of 0.714 and a specificity of 0.916. On the external validation cohort, it achieved 90% accuracy and 96% sensitivity. Conclusions: A novel machine learning ensemble model accurately predicts OCB positivity using routine laboratory data and demonstrates superior performance compared with the IgG index. This approach represents a significant step in applying artificial intelligence in laboratory medicine, with the potential to enhance diagnostic efficiency. Prospective, multicenter validation is essential for broader clinical implementation.